Search Results - "Sepúlveda Viveros, Dino"

Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison by Machado, Fernanda Lacerda da Silva, Cañás, Martín, Doubova, Svetlana V., Urtasun, Martín A., Marín, Gustavo H., Osorio-de-Castro, Claudia Garcia Serpa, Albuquerque, Flavia Caixeta, Ribeiro, Tatiane Bonfim, Pont, Lisa, Crisóstomo Landeros, José, Roldán Saelzer, Juan, Sepúlveda Viveros, Dino, Acosta, Angela, Machado Beltrán, Manuel A., Gordillo Alas, Lily Iracema, Orellana Tablas, Lourdes Abigail, Benko, Ria, Convertino, Irma, Bonaso, Marco, Tuccori, Marco, Kirchmayer, Ursula, Contreras Sánchez, Saúl E., Rodríguez-Tanta, L. Yesenia, Gutierrez Aures, Ysabel, Lin, Boya, Alipour-Haris, Golnoosh, Eworuke, Efe, Lopes, Luciane Cruz

“…Biosimilars are biological medicines highly similar to a previously licensed reference product and their licensing is expected to improve access to biological…”
Get full text

Data sources for drug utilization research in Latin American countries—A cross‐national study: DASDUR‐LATAM study by Lopes, Luciane C., Salas, Maribel, Osorio‐de‐Castro, Claudia Garcia Serpa, Leal, Lisiane Freitas, Doubova, Svetlana V., Cañás, Martín, Dreser, Anahi, Acosta, Angela, Baldoni, Andre Oliveira, Bergamaschi, Cristiane, Mota, Daniel Marques, Gómez‐Galicia, Diana L., Sepúlveda‐Viveros, Dino, Delgado, Edgard Narvaez, Lima, Elisangela, Chandia, Felipe Vera, Ferre, Felipe, Marin, Gustavo H., Olmos, Ismael, Zimmermann, Ivan R., Fulone, Izabela, Roldán‐Saelzer, Juan, Sánchez‐Salgado, Juan Carlos, Castro‐Pastrana, Lucila I., Souza, Luiz Jupiter Carneiro, Beltrán, Manuel Machado, Silva, Marcus Tolentino, Mena, María Belén, França Fonteles, Marta Maria, Urtasun, Martín A., Tarapués, Mónica, Hernández, Patricia Granja, Medero, Natalia, Herrera‐Comoglio, Raquel, Barberato‐Filho, Silvio, Galvão, Taís Freire, Luiza, Vera Lucia, Santa‐Ana‐Tellez, Yared, Rodríguez ‐ Tanta, Yesenia, Elseviers, Monique

“…Purpose Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step…”
Get full text